The Manufacturers Life Insurance Company Has $41.05 Million Stock Holdings in Revvity Inc. $RVTY

Key Points

• The Manufacturers Life Insurance Company increased its Revvity stake by 5.8% in the second quarter, holding 368,938 shares valued at approximately $41.05 million. Institutional investors collectively own 86.65% of the company.
• Revvity exceeded quarterly expectations, reporting $1.41 in EPS versus the $1.21 consensus estimate and revenue of $729.69 million. However, revenue declined 1.3% year over year, and the company guided for fiscal 2026 EPS of $5.30–$5.40.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $116.57, despite KeyCorp raising its target to $165 and maintaining an “overweight” rating.

The Manufacturers Life Insurance Company raised its stake in Revvity Inc. (NYSE:RVTY - Free Report) by 5.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 368,938 shares of the company's stock after purchasing an additional 20,278 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.33% of Revvity worth $41,048,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new position in Revvity during the second quarter worth $3,845,000. Bank of New York Mellon Corp bought a new stake in Revvity during the second quarter worth $78,766,000. California State Teachers Retirement System lifted its stake in Revvity by 19.8% in the first quarter. California State Teachers Retirement System now owns 133,809 shares of the company's stock valued at $11,723,000 after acquiring an additional 22,075 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new stake in Revvity in the second quarter valued at $4,791,000. Finally, Corient Private Wealth LLC grew its position in shares of Revvity by 985.0% in the 4th quarter. Corient Private Wealth LLC now owns 126,568 shares of the company's stock valued at $12,245,000 after acquiring an additional 114,903 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Performance

RVTY opened at $124.46 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The business has a fifty day simple moving average of $117.71 and a 200 day simple moving average of $103.21. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $133.00. The company has a market capitalization of $13.89 billion, a PE ratio of 59.27, a price-to-earnings-growth ratio of 2.20 and a beta of 1.09.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm had revenue of $729.69 million for the quarter, compared to analysts' expectations of $702.96 million. During the same quarter last year, the business earned $1.18 EPS. The company's quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts expect that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity's dividend payout ratio is 13.33%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RVTY shares. Wolfe Research began coverage on shares of Revvity in a report on Tuesday, June 2nd. They issued a "peer perform" rating on the stock. Zacks Research upgraded shares of Revvity from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. KeyCorp lifted their price target on Revvity from $125.00 to $165.00 and gave the stock an "overweight" rating in a report on Friday, September 4th. Weiss Ratings raised Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, July 30th. Finally, Sanford C. Bernstein began coverage on Revvity in a research note on Friday, June 26th. They issued a "market perform" rating and a $115.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $116.57.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.